Last updated: May 2, 2026
What form of famotidine is “preservative free”?
“Famotidine preservative free” in the market typically refers to preservative-free sterile injectables or preservative-free sterile ophthalmic/other sterile presentations made under current good manufacturing practice (cGMP). The exact regulatory definition depends on the finished product labeling and the route of administration.
Because you asked for suppliers, the practical way suppliers are identified in pharma commercial execution is by:
- API (active) manufacturers for famotidine used in injectables, and
- finished dosage manufacturers that produce sterile preservative-free drug product (fill-finish and final sterile release).
API suppliers: who makes famotidine used for sterile products?
The famotidine API supply base is broad, with manufacturing spread across multiple countries and multiple regulatory filings. However, in sterile parenteral markets, procurement is usually driven by what appears in regulatory submissions for the specific finished product (for example, ANDA/505(b)(2) for the US, or national MA dossiers in the EU), and by the approved vendor list used by the finished-dose sponsor.
Below is the supplier set that is most consistently encountered for famotidine API in global supply chains and regulatory practice (commonly seen across sterile and oral brands, including parenteral use).
Common global famotidine API manufacturing groups
| Supplier / Group |
Typical role |
Notes for preservative-free injectable pipelines |
| Aurobindo Pharma |
API and finished dose |
Large portfolio of H2-blockers; supports both generic and branded supply models. |
| Cipla |
API and finished dose |
Extensive generics manufacturing; famotidine appears in portfolio and supply chains. |
| Dr. Reddy’s Laboratories |
API and finished dose |
Often supplies molecules across multiple dose forms and markets. |
| Intas Pharmaceuticals |
API and finished dose |
Active in sterile and hospital markets via local manufacturing footprint. |
| Mylan / Viatris legacy |
API and finished dose |
Supplies established generic injectables network. |
| Sun Pharma |
API and finished dose |
Broad API manufacturing footprint supporting hospital products. |
| Teva (Teva API network historically includes API sites) |
API and finished dose |
Often appears as supplier for multiple generic sterile products. |
| Wockhardt (API and finished dose history) |
API and finished dose |
Known for global manufacturing footprint and sterile capability through partners. |
Note: API manufacturing identity can vary by lot, market, and regulatory filing. Finished product “preservative free” depends on final formulation excipients and sterile fill-finish, not on the API alone.
Finished-dose suppliers: who manufactures “preservative free” famotidine sterile product?
For “preservative free,” the key supplier is the finished drug product manufacturer (often the sponsor of the ANDA/MA) and the contract sterile fill-finish (CSFF) partner that produces the preservative-free sterile unit.
Finished-dose supplier archetypes
| Supplier type |
Typical characteristics |
What you should verify in procurement |
| Generic sterile drug product manufacturers |
Own regulatory dossier and commercial release testing |
Preservative-free statement on label and package insert; sterile filter/handling validation. |
| CSO (contract sterile operator) fill-finish houses |
Produce sterile vials/syringes under quality agreement |
Exact container closure, hold times, bioburden controls, and sterility assurance. |
| Brand sponsors / global pharma manufacturers |
Control formulation, labeling, and global supply |
Access to specific preservative-free NDC/market presentation. |
In the US, preservative-free sterile famotidine products are typically distributed through the same generic manufacturing and sterile networks that handle other hospital injectables (vials). The sponsor and manufacturer of record are discoverable from label “Repackaged by / Manufactured for” sections tied to the relevant NDC.
How procurement teams identify the real “supplier”
For “famotidine preservative free,” the procurement question is not “who makes famotidine somewhere,” but:
- Who manufactures the exact preservative-free presentation you buy (strength, container, fill volume, vial closure, kit/configuration).
- Who performs sterile fill-finish and final batch release for the exact NDC/market SKU.
That is typically evidenced by:
- US package labeling: “Manufactured for” / “Distributed by” and the listed manufacturer address.
- EU SmPC/packaging: MAH and manufacturer details on the pack and dossier.
- Regulatory database entries mapping to the exact presentation.
What to request from suppliers to lock the correct “preservative free” product
Even if a supplier lists famotidine, preservative-free must match the formulation and sterile product spec.
Procurement artifacts to demand (and that distinguish preservative-free):
- Label claim: “preservative free” on carton and inner label.
- Drug product composition: excipient list and absence of preservatives (no antimicrobial preservatives).
- Sterility and endotoxin specs: sterility method and endotoxin limits for each batch.
- Container closure system: vial type, stopper, seal method.
- Shelf life and storage: refrigerated versus room temp affects logistics and sourcing.
Key implications for supply chain selection
- API suppliers are necessary but not sufficient. Preservative-free status is driven by drug product formulation and sterile fill-finish controls.
- Fill-finish capacity and release testing dominate availability. The bottleneck is typically sterile manufacturing and release testing, not API synthesis.
- Multiple approved sources can exist for the same market SKU. If you buy by NDC/presentation, you reduce the risk of switching between different sterile manufacturing sites.
Key Takeaways
- “Famotidine preservative free” procurement hinges on the sterile finished drug product manufacturer and the exact preservative-free label/presentation, not just famotidine API makers.
- API supply for famotidine is handled by large multinational generic and specialty API networks (commonly including Aurobindo, Cipla, Dr. Reddy’s, Intas, Sun Pharma, Teva, and Viatris legacy networks, among others).
- The practical supplier shortlist for availability comes from the manufacturer of record for the specific preservative-free SKU (identified by NDC/label), plus the sterile fill-finish partner under quality agreement.
- To avoid mismatches, buyers should require composition, sterility/endotoxin specs, container closure details, and shelf-life conditions tied to the preservative-free presentation.
FAQs
-
Does famotidine API itself need to be “preservative free”?
No. Preservative-free usually refers to the finished sterile drug product formulation (excipients) and labeling.
-
Who is the most important supplier for availability of preservative-free famotidine?
The finished drug product manufacturer and its sterile fill-finish site, because sterile production and release testing drive supply.
-
Can the same API manufacturer supply multiple finished product presentations?
Yes. API suppliers can serve oral and parenteral products; preservative-free status depends on the finished formulation and process.
-
How do I verify that a supplier’s “famotidine preservative free” is the correct SKU?
Confirm the label claim, excipient list showing no preservatives, and match the exact NDC/strength/container.
-
What usually causes shortages in preservative-free injectables?
Sterile manufacturing constraints (fill-finish capacity, sterile filtration, sterility assurance, release testing throughput) rather than API synthesis alone.
References
[1] Aurobindo Pharma. Company and manufacturing information. (Company website)
[2] Cipla. Company and manufacturing information. (Company website)
[3] Dr. Reddy’s Laboratories. Company and manufacturing information. (Company website)
[4] Intas Pharmaceuticals. Company and manufacturing information. (Company website)
[5] Sun Pharma. Company and manufacturing information. (Company website)
[6] Viatris. Company and manufacturing information. (Company website)
[7] Teva Pharmaceuticals. Company and manufacturing information. (Company website)
